Related Experiment Video
Updated: Jul 2, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
[SphK-1/S1P signal pathway in CML cells]
Wen-Rong Huang1, Li-Sheng Wang, Hua Wang
1Department of Hematology, PLA General Hospital, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 23, 2008
Summary
The study found that the P210(bcr/abl) fusion protein in chronic myelogenous leukemia (CML) cells activates sphingosine kinase-1 (SphK-1). Inhibiting this protein with imatinib mesylate reduced SphK-1 activity in CML cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm driven by the P210(bcr/abl) fusion protein.
- The sphingosine kinase-1 (SphK-1)/sphingosine 1-phosphate (S1P) signaling pathway is implicated in various cancers.
- The precise role of SphK-1/S1P signaling in CML pathogenesis and its regulation by P210(bcr/abl) remain incompletely understood.
Purpose:
- To investigate the role of the SphK-1/S1P signaling pathway in CML cells.
- To determine if the P210(bcr/abl) fusion protein activates SphK-1.
- To examine the effect of imatinib mesylate on SphK-1 activity in CML cells.
Summary:
- SphK-1 and S1P receptor mRNA expression were detected in bcr/abl-positive K562 and primary CML cells using RT-PCR.
- Treatment with imatinib mesylate, a P210(bcr/abl) inhibitor, significantly reduced SphK-1 activity in a time-dependent manner.
- Results demonstrate that P210(bcr/abl) activates SphK-1 in CML cells, which express SphK-1 and various S1P receptors.
Impact:
- Provides evidence that P210(bcr/abl) directly activates SphK-1 in CML.
- Suggests the SphK-1/S1P pathway as a potential therapeutic target in CML.
- Highlights the molecular mechanisms linking the oncogenic driver to cellular signaling in CML.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...